Louisiana 2024 Regular Session

Louisiana Senate Bill SB487

Introduced
4/2/24  
Introduced
4/2/24  
Refer
4/3/24  
Report Pass
4/24/24  
Engrossed
4/30/24  
Engrossed
4/30/24  
Refer
5/1/24  
Refer
5/1/24  
Report Pass
5/21/24  
Report Pass
5/21/24  
Enrolled
5/30/24  
Enrolled
5/30/24  
Chaptered
6/19/24  
Chaptered
6/19/24  
Passed
6/19/24  

Caption

Provides for hospital drug screenings. (8/1/24)

Impact

The passage of SB 487 will necessitate changes in hospital protocols for handling suspected drug overdoses in minors. By requiring hospitals to test for fentanyl, the bill aims to provide critical data to public health authorities about the prevalence of fentanyl use among minors. Additionally, hospitals will be obligated to report any positive test results for fentanyl to the Louisiana Department of Health, contributing to a state-wide effort to understand and combat the opioid epidemic more effectively.

Summary

Senate Bill 487, sponsored by Senator Cathey and Representative Chassion, aims to enhance the monitoring of opioid usage, particularly among minors. This legislation mandates that if a minor undergoes a urine drug screening for a suspected opioid overdose at a hospital, the screening must specifically test for fentanyl. This requirement is a direct response to the growing concerns regarding the opioid crisis and the prevalence of fentanyl, which is known for its potency and potential lethality when mixed with other substances.

Sentiment

The sentiment surrounding SB 487 is generally supportive, particularly among public health advocates and lawmakers focused on addressing the opioid crisis. Proponents argue that the requirement for fentanyl screening is a proactive measure that could save lives and provide invaluable information about the usage of dangerous substances. However, there may be some concern regarding the pressure this places on hospitals and healthcare providers in terms of additional testing and reporting obligations.

Contention

While the bill is likely to receive broad support, there may be discussions regarding the potential burdens placed on hospitals to implement these testing protocols efficiently. There could also be debates surrounding issues of parental consent and the implications of testing minors. Nonetheless, the unilateral goal of the bill is to enhance public health responses to drug overdoses among youths, thereby minimizing the risks posed by opioid misuse.

Companion Bills

No companion bills found.

Previously Filed As

LA HB200

Provides relative to newborn screening for certain genetic conditions (EN SEE FISC NOTE GF EX See Note)

LA SB66

Provides relative to telehealth services. (1/1/24) (EN NO IMPACT See Note)

LA HB655

Provides relative to kratom products (RE1 +$88,100 GF EX See Note)

LA HB122

Provides relative to the mandatory screening of all newborns for early detection of the cytomegalovirus (CMV) (OR NO IMPACT See Note)

LA SB104

Provides for health insurance coverage of genetic testing for diseases and other medical conditions. (8/1/23) (EN INCREASE GF EX See Note)

LA HCR2

Provides for a hospital stabilization formula (EN +$314,552,060 SD RV See Note)

LA SB200

Provides that retaliation against an employee for an absence from work due to genetic testing or a medically necessary cancer screening shall be an unlawful employment practice. (8/1/23)

LA SB169

Provides for tracking rape kits from collection through conviction. (8/1/23) (EN +$737,541 GF EX See Note)

LA HB275

Provides relative to Concordia Parish Hospital Service District No. 1

LA HB69

Provides for the screening and diagnosis of students with respect to dyslexia (EN INCREASE GF EX See Note)

Similar Bills

No similar bills found.